WillItSurvive
Medical technology and health companies · United States

Ro

ro.co ↗

Direct-to-consumer telehealth platform selling GLP-1 weight loss drugs, labs, and prescriptions online.

Losing its protection
Assessed 22 July 2026 · Evidence as of 22 July 2026
The structural protection is eroding.
On the recordSince 22 July 2026 · Checkable from July 2026 · Every call on the record Checkpoint: FDA peptide legalization vote, a decision that could reshape compounded GLP-1 supply
The call

Ro survives as long as Novo Nordisk and Eli Lilly keep it on the approved partner list, and that list has already gotten shorter once.

Ro lets patients talk to real doctors online, get prescriptions, and pick up medicine or lab tests without leaving home, all in one app. The problem is that 40 percent of Ro's money comes from selling weight loss drugs made by Novo Nordisk and Eli Lilly, but those two companies are now selling directly to patients themselves through their own apps (NovoCare and LillyDirect) and have already kicked other telehealth companies out when it suited them. Ro also faces a newer threat: AI systems are now legally allowed to diagnose and prescribe medicine in some places, which means the main reason people needed Ro's licensed doctors may be disappearing. The one thing that could save Ro is if the drug makers decide they still need partners like Ro to reach customers, but that is something Novo and Eli Lilly control, not Ro.

Why
01
AI pressure: Doctronic. Doctronic got legal authorization to practice medicine in Utah in Dec 2025, an AI doctor that could skip Ro's clinician layer entirely. Could AI do the core job? Only partly.
02
Bigger players: Novo Nordisk and Eli Lilly (NovoCare, LillyDirect). Novo cut Hims & Hers from Wegovy access in June 2025. Ro's entire GLP-1 business runs on the same kind of revocable contract. Could a giant copy it? Yes, easily.
03
What protects it. Ro is one of only two telehealth firms (with LifeMD) Novo kept direct NovoCare access for after the June 2025 cuts.
What would change this call
Novo Nordisk or Eli Lilly removes Ro from preferred-partner drug access. Would show Ro's supply deal is revocable, as happened to Hims & Hers.
Doctronic or similar AI system wins prescribing authorization beyond Utah. Would show AI-native rivals bypassing the licensed-clinician moat Ro relies on.
Ro closes a primary funding round priced below the $2.3B secondary estimate. Would confirm investor-implied value has fallen sharply from the $7B 2022 round.
Key numbers
  • GLP-1 drugs are 40% of revenue, up from 3% in 2021 (2024-12-31)
  • Secondary valuation ~$2.3B, down 67% from $7B in 2022 (2026-06-30)
  • No priced funding round in over 4 years (2026-06-30)
Named risks
  • Ro's GLP-1 revenue depends on revocable manufacturer contracts; Novo already cut Hims in June 2025. Severity: high
  • Secondary-market valuation estimated at $2.3B in June 2026, down from $7B peak, signaling down-round pressure. Severity: medium
  • AI systems like Doctronic gaining legal prescribing authority erodes licensed-provider moat. Severity: medium
  • Celebrity marketing (Serena Williams Super Bowl ad, Feb 2026) drew public and regulatory scrutiny. Severity: medium
  • No priced funding round since Feb 2022 and no IPO path limits liquidity and capital access. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Hims & Hers HealthcontestingFramed as telehealth duopoly with Ro over GLP-1 patients, Feb 2026
Novo Nordisk / Eli Lilly (NovoCare, LillyDirect)gaining onManufacturers building direct-to-patient channels that could bypass Ro
Doctronic (AI)gaining onGained legal authorization to practice medicine in Utah, Dec 2025
LifeMDcontestingOne of only two firms besides Ro retaining NovoCare integration since Jun 2025
Questions people ask
Is Ro profitable in 2026?
No public profitability figure exists for Ro. Third-party researcher Sacra estimated 2024 annualized revenue near $598M, up 66% from 2023, but Ro has not disclosed profit, and no S-1 or audited financials are public as of mid-2026.
Who is Ro's biggest competitor?
Hims & Hers Health (NYSE: HIMS) is Ro's closest rival, both vertically-integrated telehealth firms competing for the same GLP-1 weight-loss patients; one February 2026 industry analysis explicitly framed the pair as a telehealth duopoly.
Could AI replace Ro's doctors?
Partially. Doctronic, an AI system, gained legal authorization to practice medicine in Utah in December 2025, a first crack in the licensed-provider barrier that currently protects prescribing platforms like Ro from pure-AI substitution nationwide.
Is Ro planning to go public?
Not imminently. CEO Zach Reitano said in October 2024 he was 'not rushing' an IPO, and as of mid-2026 Ro has filed no S-1, despite broader 2026 IPO-market momentum among VC-backed firms.
What is Ro's current valuation?
Ro's last confirmed primary round valued it at $7B in February 2022. A secondary-market tracker (TrueUp) estimated its implied valuation at roughly $2.3B as of June 2026, a third-party estimate, not a company-confirmed figure, down about 67%.
Did Novo Nordisk drop Ro like it dropped Hims & Hers?
No. Novo Nordisk terminated its Hims & Hers Wegovy partnership in June 2025, but Ro (with LifeMD) remained one of only two telehealth firms retaining direct NovoCare integration, later launching a Wegovy pill integration in January 2026.
Timeline
  • 2026-07-20FDA advisory panel vote underway on legalizing compounded peptides like BPC-157, TB-500
  • 2026-07-10Novo Nordisk plans to cut ~9,000 jobs, 11.5% of global workforce
  • 2026-02-09Serena Williams Super Bowl LX GLP-1 ad for Ro draws public criticism
  • 2026-01-05Ro launches Wegovy pill integration with Novo Nordisk; publishes Obesity journal outcomes study
  • 2026-01-01Ro announces research collaboration with Amgen on GLP-1 access barriers
  • 2025-12-01Doctronic AI system authorized to practice medicine in Utah
  • 2025-08-01Serena Williams GLP-1 campaign drives 27% jump in GLP-1 bookings on Zocdoc
  • 2025-06-01Novo Nordisk terminates Hims & Hers Wegovy partnership
  • 2024-10-22CEO Zach Reitano says he is not rushing an IPO
  • 2022-02-14Ro raises $150M at $7B valuation, its last priced primary round
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources